TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01908517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine Electronic Reminders
Description: The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
Study: NCT02561299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Orbital Atherectomy System
Description: Orbital Atherectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 014 Drug Coated Balloon
Description: Drug Coated Balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 014 Drug Coated Balloon
Description: Drug Coated Balloon
Study: NCT03827590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test
Description: three times a day for five days
Study: NCT00687167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg Capsule
Description: 100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide (Zonegran®) 100 mg Capsule
Description: 100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
Study: NCT02382328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid
Description: comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
Study: NCT01176110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Perfect Temp
Description: The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Perfect Temp
Description: The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
Study: NCT02225665

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728mR-T
Description: -SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728mR-T
Description: - SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: - IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: - IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
Study: NCT02608970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study: NCT03582761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
Study: NCT00399971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex Vivo Immunotherapy
Description: Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ex vivo immunotherapy
Description: i.v. infusions, once a week, at least 6 to 12 months
Study: NCT01478282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: 20 mg/day, oral administration maintained for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: 150 mg/12 hours, administered orally, treatment maintained for 5 days
Study: NCT00831636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-4055
Description: D1-5 and D8(+2)-12(+2) q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-4055
Description: IV administration day 1-5 and day 8-12 in a 4 week schedule
Study: NCT03915665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-powder
Description: Erythritol powder using air-powder device
Study: NCT01147978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: End of ICU stay conference
Description: Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
Study: NCT01189500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Period 1-Tamoxifen 40mg on study day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Desvenlafaxine Succinate Sustained Release
Description: Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
Study: NCT01774825

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IQP-CL-101
Description: 2 softgels twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 softgels twice a day
Study: NCT05515016

Intervention type: PROCEDURE
Group type: OTHER
Intervention: chin enhancement with a fatty flap sculpted from the double chin
Description: Under general anesthesia, an incision was made behind the submental crease followed by the excision of the skin excess. The preplatysmal fatty compartment was individualized through a subcutaneous dissection. Then, the lower part of the preplatysmal fat was cut to start its separation from the platysma muscle, thus obtaining a real vascularized fatty flap. This flap could be folded on itself, then easily turned over to be fixed on the muscular layer of the chin.
Study: NCT04919941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Guide to Conservative Care
Description: The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
Study: NCT02596321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitizax
Description: Allergen extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT01071447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic vs rheumatologist-led clinic
Description: The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led clinic vs rheumatologist-led clinic
Description: The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
Study: NCT03099122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-thymocyte Immunoglobulin
Description: Pharmaceutical form: creamy-white powder~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pharmaceutical form: powder~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Na
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01482130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heavy, explosive strength training
Description: All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: recommendations
Description: The control group will be encouraged to follow a training program according to recommended exercise guidelines:~* Weight bearing activities (walking, jogging or strength training)~* 30 - 60 minutes, 3 - 5 times each week~* A total of 2 - 3 hours each week should be achieved
Study: NCT05321329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
Study: NCT02742441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Topical Foam containing no active drug
Study: NCT01612676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 202158
Study: NCT02169011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latissimus Dorsi Flap Reconstruction
Description: Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Flap Reconstruction
Description: Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
Study: NCT02307630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 124I-Humanized 3F8
Study: NCT05551468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StayFine guided app-based personalised intervention modules
Description: Participants work on guided app-based personalised intervention modules in the StayFine app over the course of three months. The modules are selected by the participant based on shared decision making and a personalized advice. The intervention is based on Preventive Cognitive Therapy (PCT) with elements of Cognitive Behavioral Therapy (CBT) and Positive Psychology. Modules are: psycho education (mandatory), cognitive restructuring (mandatory), positive affect, behavioral activation, exposure, wellness, sleep and a relapse prevention plan (mandatory).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: StayFine app-based monitoring
Description: Monitoring six times per day for two weeks in the StayFine app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StayFine app-based monitoring
Description: Monitoring six times per day for two weeks in the StayFine app.
Study: NCT03364153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avacincaptad pegol
Description: Intravitreal Injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Intravitreal Injection
Study: NCT03976297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Tower
Description: A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
Study: NCT03827590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Control 1
Description: three times a day for five days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Control 2
Description: three times a day for five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three times a day for five days
Study: NCT04552223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.
Study: NCT03407768

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individualized interventions
Description: A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques.
Study: NCT02467400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: beta blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: beta blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: beta blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: beta blocker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00252915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF (verum)
Description: sagramostim
Study: NCT04250220

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: e-Health based strategy: PPG-based screening using a smartphone and ECG patch
Description: PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch
Study: NCT02468674

Intervention type: DRUG
Group type: OTHER
Intervention: bimagrumab
Description: bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Study: NCT03686865

Intervention type: DEVICE
Intervention: dental implants
Description: extraction sockets regenerated with xenograft
Study: NCT03350178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transfer
Description: transfer of fecal microbiota from healthy donor to the patients
Study: NCT00101491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Communication DVD video
Description: Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Communication DVD video
Description: Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
Study: NCT00713063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: 12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: 12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
Study: NCT02967458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microsphere Intravenous Suspension
Description: The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
Study: NCT01914913

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BMMNCs
Description: Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
Study: NCT03664401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerecis Oral™

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: A free gingival autograft from patient palate placed and secured on wound bed
Study: NCT00941889

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Description: 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
Study: NCT01122030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets or solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets or solution for oral administration
Study: NCT01471860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Management
Study: NCT02590887

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink manufactured from lupine peptides
Description: Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage.
Study: NCT02729948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tethered Capsule Endoscope
Description: Undergo TCE
Study: NCT00630812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled mannitol
Description: 400 mg BD for 26 + 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
Study: NCT02387619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine
Description: Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine
Description: Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Telmisartan/Amlodipine
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Telmisartan/Amlodipine
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Telmisartan/Amlodipine
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Telmisartan/Amlodipine
Description: Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
Study: NCT02694211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ProMES
Description: Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
Study: NCT02927873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) low dose formulation vaccine
Description: 2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) middle dose formulation vaccine
Description: 2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.